REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Taiwan Advance Bio-Pharmaceutical Inc. (Taiwan, China)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: Taiwan Advance Bio-Pharmaceutical Inc. Profile Updated: July 05, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Taiwan Advance Bio-Pharmaceutical Inc.(stock code: 4186) specializing in testing reagents of the biotechnology. The major shareholder of the Company is Taiwan Economic Department, Taiwan Sugar Union and so on. Taiwan Advance Bio-Pharma was established in year 2000 and the head office is located in Taipei.

Headquarters
12F., No.25, Ln. 169, Kangning St., Xizhi Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the Taiwan Advance Bio-Pharmaceutical Inc. report to view the information.

Website: http://www.biotest.com.tw

Basic Information
Total Employees:
Purchase the Taiwan Advance Bio-Pharmaceutical Inc. report to view the information.
Outstanding Shares:
Purchase the Taiwan Advance Bio-Pharmaceutical Inc. report to view the information.
Financial Auditors:
Purchase the Taiwan Advance Bio-Pharmaceutical Inc. report to view the information.
Incorporation Date:
May 25, 2000
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
12.26%
Purchase this report to view the information.
3.62%
Purchase this report to view the information.
1%
Purchase this report to view the information.
0.85%
Purchase this report to view the information.
0.46%
Subsidiaries
Glyconex Incorporation
2.19%
2.02
2.02%
Company Performance
Financial values in the chart are available after Taiwan Advance Bio-Pharmaceutical Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Net sales revenue
17.73%▲
Total operating revenue
17.96%▲
Operating profit (EBIT)
N/A
EBITDA
N/A
Net Profit (Loss) for the Period
87.91%▲
Total assets
-1.54%▼
Total equity
9.93%▲
Operating Profit Margin (ROS)
N/A
Net Profit Margin
25.42%▲
Return on Equity (ROE)
15.61%▲
Debt to Equity Ratio
-4.49%▼
Quick Ratio
-0.04%▼
Cash Ratio
-0.08%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo